| Revenue growth | H1 revenue rose 31% YoY to ₹302.9cr; Q2 rose 15%. |
|---|---|
| Margins | EBITDA margins normalized to 38% after exceptional low raw material gains. |
| Demand visibility | Strong visibility in infant nutrition and battery materials; US recovering. |
| Management confidence | Confident, focusing on high-barrier certifications like USFDA and CEP. |
Growth
H1 revenue grew 31% YoY to ₹302.9cr; PAT increased to ₹78cr. Growth is diversifying via the NSS Ireland acquisition.
Outlook
Targeting 100,000 MT capacity in Dahej by FY28. Normalizing inventory to 140-150 days by mid-term.
Risks
High working capital days (195) and US tariff uncertainty affecting 50% of US business are concerns.
Earnings Call filed with NSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,175.00
- Market cap
- ₹13,271 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.7×Sector 47.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Other Announcement
Sudeep Pharma Limited corrected a clerical error regarding the number of attendees at its Annual General Meeting, updating the count from 45 to 44.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Annual General Meeting
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026. The meeting transacted business including financial statement approval, director appointments, dividend declaration, and ESOP schemes.
Sudeep Pharma Capital Structure Change
Nuvama Crossover Opportunities Funds reduced their stake in Sudeep Pharma Ltd. The promoter field is 'No', indicating a non-promoter equity transaction.